^
    Back
    Association details:
    Biomarker:CXCL8 elevation
    Cancer:Head and Neck Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Radiother Oncol
    Title:

    Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study

    Published date:
    06/12/2020
    Excerpt:
    Higher than median levels of three serum markers were negatively associated with the 2-year LRC rate in the overall patient cohort: Osteopontin, IL8 and FasL2 (p≤0.05).
    DOI:
    10.1016/j.radonc.2020.06.011